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Quantitative magnetic resonance imaging (MRI)-based biomarkers, which capture physiological and func-
tional tumor processes, were evaluated as imaging surrogates of early tumor response following chemoradio-
therapy in glioma patients. A multiparametric extension of a voxel-based analysis, referred as the parametric
response map (PRM), was applied to quantitative MRI maps to test the predictive potential of this metric for
detecting response. Fifty-six subjects with newly diagnosed high-grade gliomas treated with radiation and
concurrent temozolomide were enrolled in a single-site prospective institutional review board-approved MRI
study. Apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired
before therapy and 3 weeks after therapy was initiated. Multiparametric PRM (mPRM) was applied to both
physiological MRI maps and evaluated as an imaging biomarker of patient survival. For comparison, single-
biomarker PRMs were also evaluated in this study. The simultaneous analysis of ADC and rCBV by the
mPRM approach was found to improve the predictive potential for patient survival over single PRM mea-
sures. With an array of quantitative imaging parameters being evaluated as biomarkers of therapeutic re-
sponse, mPRM shows promise as a new methodology for consolidating physiologically distinct imaging pa-
rameters into a single interpretable and quantitative metric.
INTRODUCTION
The prognosis of glioblastoma (GBM) patients remains dismal
because with the current standard of treatment patients have an
average median survival of only 14 to 16 months (1, 2). Radia-
tion therapy with concomitant temozolomide continues to be
the standard of care for treatment of patients with GBM, and
new therapies are urgently needed. Improving patient manage-
ment (and ultimately the outcome) will require more sensitive
and optimized imaging outcome metrics that will provide earlier
biomarkers of therapeutic response accompanied by improved
therapeutic strategies. Determining treatment response and clin-
ical decision-making is currently based on radiologically assess-
ing tumor volume measurements 10 weeks after the initiation of
treatment. However, evaluating GBM magnetic resonance im-
aging scans (MRIs) requires differentiating responding tumors
from progressive disease, which can be complicated by alterations
in MRI tumor contrast as a result of therapeutically associated
disruption of the blood–brain barrier (BBB), a phenomenon termed
pseudoprogression that mimics true disease progression (3, 4).
Thus, identifying neuroimaging methods that can assess treat-
ment response early as well as distinguishing pseudoprogression
from tumor progression would be a major advance in neurora-
diology and the clinical management of GBM patients (5). Be-
cause changes in imaging tumor volume measurements can be
confounded by BBB permeability changes along with inflam-
matory processes, efforts to improve the accuracy of patient
response assessment have resulted in updated standardized clin-
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Neuro-Oncology Working Group (RANO) (4). These new criteria
address limitations with the previous response assessment cri-
teria (Macdonald criteria) (6) by advocating the use of additional
physiologically sensitive imaging biomarkers for a more accu-
rate tumor response assessment. RANO emphasized that future
response criteria will integrate newly advanced MRI techniques
such as perfusion imaging (4) after rigorous clinical validation.
Thus, new developments will require integrating not only 1 but
multiple MRI parameters (anatomical and/or physiological) to
simultaneously follow morphological and physiological modi-
fications induced by current and emerging therapies.
Anatomical MRIs, clinical status, and corticosteroid-depen-
dency assessment are the standards for treatment response as-
sessment in GBM patients. Quantitative MRI may provide com-
plementary information related to early changes in tumor
pathophysiology following treatment interventions. Quantita-
tive MRI metrics widely under evaluation as metrics of tumor
response include relative cerebral blood volume (rCBV) and
apparent diffusion coefficient (ADC). Tumor hemodynamics can
be assessed and quantified using rCBV metrics obtained through
dynamic susceptibility contrast (DSC) MRI exams (7-10). This
measure, as well as other MRI-based hemodynamic parameters,
has shown promise as a surrogate of clinical outcome for GBM
patients treated with chemoradiotherapy as well as with anti-
vascular/antiangiogenic agents (7, 8, 11-13). In addition, diffu-
sion-weighted MRI (DW-MRI) has emerged as a method capable
of measuring the random thermal (Brownian) motion of water
molecules within tumor tissue and as such is sensitive to ther-
apeutically associated changes in the tumor microenvironment
(14-19). A decrease in tumor cellularity resulting from the kill-
ing of tumor cells following therapy has been associated with an
increase in water diffusivity reflected in the ADC (15). This trend
has been observed in preclinical and clinical studies, supporting
the notion of DW-MRI as a surrogate imaging biomarker for
treatment response assessment in oncology (20-22).
Evaluating the efficacy of quantitative imaging as biomark-
ers of therapeutic response has relied on obtaining summary
statistics (eg, mean and median) over the entire tumor volume.
The attractiveness of this analytical approach is the ease of
implementation, reduction to a single scalar quantity, and the
availability of software to implement such an analysis. None-
theless, this approach has limitations because statistical mea-
sures calculated from quantitative tumor values can become
attenuated when tumors exhibit heterogeneities in their re-
sponse pattern; that is, different parts of the glioma respond
differently to treatment (23, 24). To address this issue, a voxel-
based method referred to as a parametric response map (PRM)
has been developed that overcomes the lack of sensitivity in
histogram-based techniques to quantify the evolution of treated
tumors using quantitative maps (11, 25). In the context of
DW-MRI, PRM is referred to as functional diffusion mapping
(fDM) and has been shown to be an independent indicator of
overall survival in a cohort of glioma patients (20, 25). The fDM
imaging biomarker has also been demonstrated to predict out-
comes in bone metastases and breast cancer (26). In 2009, PRM
was demonstrated to improve the effectiveness of rCBV (11, 27)
in predicting overall survival in glioma patients treated with
chemoradiotherapy. In these studies, a larger tumor portion of
PRMrCBV predicted shorter overall survival. More importantly,
PRM was described as a general analytical technique that could
be applied to multimodal quantitative maps for voxel-based
tracking of disease status (11) and progression and has since
been applied across a wide variety of imaging parameters
(28-30).
This study reports the outcome of a prospective single-
center trial of glioma patients that evaluated the ability of
multi-PRM (mPRM) to predict overall survival. We incorporated
2 physiologically sensitive quantitative imaging maps (ie, rCBV
and ADC) into a single mPRM biomarker response metric. This
approach retained detailed spatial information on heterogeneity
in the tumor response pattern that was critical for improving the
predictive sensitivity of the quantitative maps. This study dem-
onstrates that in our patient cohort incorporating multiple met-
rics into the mPRM voxel-based analysis approach improved the




Patients with pathologically proven high-grade gliomas were
enrolled on a protocol of intratreatment MRI as part of a single-
site prospective trial. Informed consent was obtained, and the
use of images and medical records was approved by the Univer-
sity of Michigan Institutional Review Board. Only patients with
contrast-enhancing tumors of 4 cm3 or greater were included in
this study. Fifty-six patients were evaluated before therapy and
3 weeks after the initiation of chemoradiotherapy (Table 1),
which consisted of concomitant and adjuvant temozolomide
with radiation. Part of this patient cohort had been used
previously in published work that investigated the prognostic
value of PRM applied to the individual parameters ADC and
rCBV and a composite model of PRM applied to these 2
parameters (11, 20, 31).
Radiotherapy was delivered over 6 weeks using standard
techniques with a 2.0 to 2.5-cm margin on either the enhancing
region on gadolinium (Gd)-enhanced scans or the abnormal
signal on T2-weighted scans to 46 to 50 Gy, with the central
gross tumor treated to a final median dose of 70 Gy. Chemo-
therapy was commonly administered in both groups depending
upon clinical circumstances (Table 1). No patient received anti-
angiogenic therapy during their primary treatment, although
some received bevacizumab (Avastin; Genentech) at the time of
progression.
MRIs
MRIs were performed 1 week before therapy and 3 weeks after
therapy had begun. DW- and dynamic susceptibility contrast
(DSC)-MRI and standard MRI (fluid attenuation inversion recov-
ery, T2-weighted, and Gd-enhanced T1-weighted MRI) were
conducted on either a 1.5 T Signa (General Electric Medical
Systems) or 3 T Achieva (Philips Medical Systems) system. In
this study, repeat scans were always acquired on the same MRI
scanner as the baseline scan. Radiologic response at 10 weeks
was based on changes in tumor volume on T1-weighted con-
trast-enhanced MRIs and steroid doses and was classified as
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complete response, partial response, stable disease, and progres-
sive disease (6). Steroid doses were recorded before each scan,
weekly during radiotherapy, and at each follow-up (32).
DW-MRIs were acquired using a single-shot, spin-echo,
diffusion-sensitized, echo planar imaging acquisition sequence.
Scans acquired on the 1.5 T system were obtained from 24 6-mm
axial-oblique sections using a 22-cm field of view (FOV) and
128  128 matrix with b factors of 0 and 1000 s/mm2 along 3
orthogonal directions (repetition time [TR]  1000 ms; echo
time [TE]  71-100 ms; number of averages [NS]  1). Images
obtained using the 3 T MRI scanner acquired at least 28 4-mm
axial-oblique sections through the brain using a 24-cm FOV and
128  128 matrix (TR  2636 ms; TE  46 ms; NS  1 for a b
value of 0 and NS  2 for a b value of 1000 s/mm2). Parallel
imaging (sensitivity encoding factor  3) was used on the 3 T
scanner to reduce spatial distortion. The diffusion-weighted
images for the 3 orthogonal directions were used to calculate
ADC maps for all patients (20).
To obtain DSC-MRI data, a gradient echo planar imaging
pulse sequence was used with the following acquisition param-
eters: TR  1.5 to 2 s; TE  50 to 60 ms; FOV  22 cm; matrix 
128  128; flip angle  60°; 4-6-mm thickness; 14-20 slices;
0-mm gap. Gd-DTPA (Bayer HealthCare Pharmaceuticals) was
injected intravenously with a dose of 0.05 to 0.1 mL/kg as a
bolus using a power injector at a rate of 2 mL/s and followed
immediately by 15 cc of saline flush at the same rate. A Gd-
enhanced T1-weighted image was then acquired. All CBV maps
were computed from DSC images as previously described (33).
To mitigate the effects from leakage, a preinjection of contrast
agent before a second bolus was given during the dynamic T2*
imaging (ie, DSC-MRI). In addition, a sufficiently long TR was
employed to reduce T1 weighting. To assess differences in tumor
blood volume during chemoradiotherapy and among patients,
all CBV maps were normalized to CBV values in white matter
regions that were contralateral to the tumor to generate rCBV
maps. (For simplicity in notation, relative blood volumes for










P ValueNo. % No. % No. % No. %
Age (y) 55 (15) 50 (15) 49 (12) 63 (13) .002
Sex
Male 24 43 6 46 10 50 8 35 .58
Female 32 57 7 54 10 50 15 65
Pathology (grade)
3 10 18 4 31 2 10 4 17 .32
4 46 82 9 69 18 90 19 83
Karnofsky performance test
70 43 77 3 23 2 10 8 35 .14
70 13 23 10 77 18 90 15 65
Location
Frontal/temporal 35 63 9 69 12 60 14 61 .85
Other 21 37 4 31 8 40 9 39
Tumor volume (mL) 37 (27) 43 (22) 22 (15) 47 (33) .01
Radiological response*
Stable disease/partial response 24 52 10 91 8 53 6 30 .02
Progressive disease 20 44 1 9 6 40 13 65
Surgery
Biopsy 21 38 2 15 5 25 14 61 .04
Subtotal 23 41 8 62 9 45 6 26
Near guided tissue regeneration 12 21 3 23 6 30 3 13
Radiation therapy (Gy) 68 (9) 70 (8) 68 (9) 66 (9) .5
Chemotherapy*
Any 54 96 13 100 20 100 21 91 .16
Temozolomide 52 93 13 100 20 100 19 86 .06
Temozolomide  radiotherapy 31 55 8 62 13 65 10 44 .32
Bold P values indicate statistical significance. The asterisk indicates omitted data for radiological response (10 missing and 2 not available) and
chemotherapy (1 missing for “Any”). Likelihood ratio was performed for sex, grade, Karnofsky performance test, location of surgery, and chemotherapy.
An ANOVA with a Bonferonni post hoc test was used for age, tumor volume, and radiation therapy dose.
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both brain and tumor have been denoted by the abbreviation
rCBV throughout this article.) White matter regions of interest
that were used for normalization were contralateral to the tumor
and regions that received an accumulated dose  30 Gy and
avoided regions of partial volume averaging or regions with
susceptibility artifacts.
Postprocessing Images
All image data were registered to pretreatment Gd-enhanced
T1-weighted images using mutual information as an objective
function and the Nelder–Mead simplex as an optimizer (34).
Both differently and similarly weighted serial MRIs for the same
patient were registered assuming a rigid-body geometric rela-
tionship (ie, rotate and translate). After registration, brain tu-
mors were manually contoured by a neuroradiologist over the
contrast-enhancing regions of the tumor on Gd-enhanced T1-
weighted images.
The PRM of any single parameter (PRMX, where X denotes
any parametric map such as ADC and rCBV) was determined by
first calculating the difference between X (X  mid-X 
baseline X) for each voxel within the tumor before and 3 weeks
after the initiation of treatment. Voxels that yielded a X value
greater than a predetermined threshold were designated red (ie,
rCBV  1.2; ADC  55; PRMX). Blue voxels represented
volumes whose parameter value decreased by more than the
threshold (ie, rCBV 1.2; ADC 55; PRMX), and green
voxels represented voxels within the tumor that were unchanged
(ie, |rCBV|  1.2; |ADC|  55; PRMX0). Thresholds were set to
1.2 and 55 for rCBV and ADC, respectively, as determined from
previously published work (11, 20, 25). In brief, healthy contralat-
eral brain tissue from registered parameter maps was contoured to
generate voxels with paired parameter values at baseline and 3
weeks after treatment was initiated. A linear regression was applied
to the data, and the 95% confidence interval (CI) of the fit was used
as the threshold for each of the parameters. Thresholds were deter-
mined using a subset of patients from this cohort as described in
previously published studies (11, 20, 25).
Multiparametric response mapping was applied to ADC and
rCBV to generate analytical indices sensitive to changes in both
quantitative maps (Figure 1). After image registration as previ-
ously described, all serial ADC and rCBV maps shared the same
Figure 1. Schematic of the mul-
tiparametric PRM technique. (A)
Parametric maps of ADC from
DW-MRI (left) and rCBV from
DSC-MRI (right) acquired before
and midway through therapy. (B)
The PRM approach was applied
to the individually ADC and
rCBVs, resulting in 3 classifica-
tions each. PRM results are pre-
sented as a 3-color overlay that
represents regions in which tumor
parameter values (ie, ADC or
rCBV), based on predetermined
thresholds, are unchanged (green
voxels), significantly increased
(red voxels), or significantly de-
creased (blue voxels). (C) The
individual PRMs are combined,
resulting in 9 classifications (2
parameters and 3 classes, result-
ing in 32  9 classes for mPRM).
Analogous to mPRM, results are
presented as a visual map in
which individual voxels are col-
ored by classification as well as
presented within a scatter plot.
Global measures are presented
as relative tumor volumes and
calculated as the sum of all vox-
els in a class normalized to the
tumor volume.
Multiparametric Voxel-Based MRI as a GBM Response Biomarker
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spatial geometric space, with each voxel having temporal pairs
for each biomarker: baseline and midtreatment values of ADC
and rCBV. As described previously, PRM applied to a single
biomarker results in 3 classifications; when applied to 2 bio-
markers voxels it is separated into 9 classifications (3 classifi-
cations per biomarker and 2 biomarkers [32] equal 9 classifica-
tions.) The notation used to indicate the mPRM classifications is
analogous to PRM for a single biomarker (Figure 1). For exam-
ple, the volume fraction of tumor characterized as having red on
the PRMADC map (PRMADC) and blue on the PRMrCBV map
(PRMrCBV) is named mPRMADC/rCBV.
Statistical Analysis
The 3 classifications for PRMADC and PRMrCBV and all 9 classi-
fications generated by mPRMADC/rCBV were assessed for predict-
ing 1-year survival using a receiver operating characteristic
(ROC) analysis. The patient population was stratified for each
significant metric per PRM model (ie, single and multiparamet-
ric) based on optimal cutoffs that maximize sensitivity and
specificity in the ROC analysis. Significant single PRM indices
were used to generate a 3-tier (ie, composite) PRM model using
the same procedure as described in previously published work
(31). In brief, PRMADC and PRMrCBV indices that resulted in a
significant prediction of 1-year survival after ROC analysis were
combined to stratify the patient population into 3 categorical
therapeutic assessments: responders, nonresponders, and inter-
mediate. Patients were designated nonresponders when both
PRM indices predicted nonresponding, whereas patients were
designated responders when both PRM indices predicted re-
sponding. For cases in which PRM indices disagreed, patients
were designated intermediate. Because there are 9 metrics gen-
erated by the mPRM analysis, multiple metrics may significantly
stratify the patient population based on 1-year survival. In this
case, the same 3-tier procedure in combining patient stratifica-
tion by PRMADC and PRMrCBV was applied to the significant
mPRM indices. Assessing overall survival for all PRM and
mPRM models was determined using a Kaplan–Meier analysis
with a log-rank test. A multivariate Cox regression with forward
entry was used to compare the 3-tier mPRM model to the
single-parameter PRM, 3-tier PRM, and individual mPRM mod-
els. A secondary analysis was conducted to assess differences in
clinical characteristics among outcome groups defined by the
3-tier mPRM model using either a univariate ANOVA with a
Bonferroni post hoc test to control for multiple comparisons or
a likelihood ratio test. All statistical computations were con-
ducted with a statistical software package (SPSS Software Prod-
ucts), and results were declared statistically significant at the
2-sided 5% comparison-wise significance level (P  .05).
RESULTS
Patient Characteristics
A total of 57 patients with high-grade glioma was included in
this prospective study (Table 1). The median survival for the
population, as determined by the Kaplan–Meier analysis, was
12.8 months (95% CI  7.2, 18.4), with 50% of the patient
population realizing 1-year survival. Patients who died before 1
year had a median survival of 7 months (95% CI  5.4, 8.6),
whereas those whose survival was beyond 1 year had a median
survival of 35.1 months (95% CI not available).
mPRM was analyzed by first generating PRM results for
individual metrics by spatially aligning temporally paired ADC
and rCBV maps to a single geometric frame (Figure 1A) and then
Figure 2. Assessment of predictive mPRM indices. (A) For ease of visualization, the 9 classes generated from the individual
PRMs, in which plus (), minus (), and 0 represent voxel values that increase, decrease, or remain unchanged, respectively
(color code demonstrated in Figure 1), were simplified to a 3-classification scheme. Voxels were color-coded as red for
mPRMADC/rCBV0, blue for mPRMADC0/rCBV, and green for the remaining 7 classifications. (B) Predictive mPRM indices were
identified by assessing the potential of the 9 indices to predict 1-year survival using an ROC analysis. Significant ROC stratifi-
cation was observed in 2 of the 9 classes: mPRMADC/rCBV0 and mPRMADC0/rCBV. These results were used to determine the
cutoffs that maximize both sensitivity and specificity for each metric. Cutoffs for response stratification were determined to
have relative volumes (RVs) of 2.6% for mPRMADC/rCBV0 (responders: RV  2.6%; nonresponders: RV  2.6%) and 4.8%
for mPRMADC0/rCBV (responders: RV  4.8%; nonresponders: RV  4.8%).
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classifying voxels based on previously published thresholds
(Figure 1B) (11, 20). Merging the individual PRM data to a single
new mPRM resulted in 9 classifications based on changes of
both ADC and rCBV at the voxel level (Figures 1C and 2A). Key
mPRM classifications were identified using an ROC analysis to
assess the potential of each of the 9 classifications for predicting
1-year survival.
In all, 2 of the 9 classifications were identified as predictive
of 1-year survival (Figure 2B). The mPRM indices with signifi-
cantly increasing ADC values and unchanged rCBV
(mPRMADC/rCBV0) values had an area under the curve (AUC) of
0.66 (P  .04), whereas mPRM indices with unchanged ADC and
significantly decreasing rCBV values (mPRMADC0/rCBV) had an
AUC of 0.684 (P  .02). The remaining 7 indices had an AUC
near random, with P  .4. To simplify the graphical represen-
tation on a 3-dimensional image, all voxels classified as
mPRMADC/rCBV0 were color-coded red, those classified as
mPRMADC0/rCBV were blue, and the remaining voxels were
green (Figure 2A). The optimal cutoffs for patient stratification
for mPRMADC/rCBV0 and mPRMADC0/rCBV were found to be
2.6% and 4.8% of the tumor volume, respectively. Near-signif-
icant results from ROC analyses were observed for PRMADC
(AUC  0.651, P  .057, cutoff  4.8%) and PRMrCBV (AUC 
0.650, P  .058, cutoff  5.5%).
Figure 3 presents representative axial mPRM slices and
corresponding scatter plots from 2 patients in which both indi-
ces of mPRM identified each patient as a responder or nonre-
sponder 3 weeks into therapy. Figure 2A shows the color coding
for the 3-color model. The responder was found to have an
mPRMADC/rCBV0 at 10% of the tumor volume, with 2% of the
tumor classified as mPRMADC0/rCBV. In contrast, the tumor
volume from the nonresponder consisted of less than 1% of
mPRMADC/rCBV0, yet 14% consisted of mPRMADC0/rCBV. Al-
though both patients were diagnosed as having stable disease by
the Macdonald criteria, the overall survivals were quite differ-
ent, with the responder and nonresponder having survival times
of 64 and 7 months, respectively.
For an imaging biomarker to be clinically feasible for treat-
ment management, it must be demonstrated as a surrogate
marker of overall survival. Figure 4 shows the Kaplan–Meier
survival plots for the mPRM indices as well as the combined
mPRM model. All analyses produced significant results. As
observed in Figure 4A, mPRMADC/rCBV0 generated a P  .01,
whereas those identified as nonresponders (n  29) had a me-
dian survival of 8.8 months (95% CI  5.6, 12.0), and responders
(n  27) had a median survival of 17.4 months (95% CI not
available). Similar results were observed for mPRMADC0/rCBV,
with a P  .01 and median survivals for nonresponders (n  37)
Figure 3. Representative slices from patients identified as responders and nonresponders by mPRM. (A) Presented are
T1-weighted post-Gd axial slices with a tumor contour generated from intersecting pretreatment and 3-weeks-of-treatment
contours and (B) mPRM overlays with (C) a corresponding mPRM scatter plot for patients identified by mPRM as re-
sponder (top) or nonresponder (bottom). The responder was identified as having relative tumor volumes of 10% and 2%
for mPRMADC/rCBV0 and mPRMADC0/rCBV, respectively. In contrast, the nonresponder had relative tumor volumes of
0% and 14% for mPRMADC/rCBV0 and mPRMADC0/rCBV, respectively. Both responders and nonresponders were diag-
nosed as having stable disease by the Macdonald criteria yet had overall survivals of 64 and 7.1 months, respectively.
Scatter plot axes are presented as pretherapy ADC (ie, baseline) for the x-axis and 3-week follow-up ADC for the y-axis.
Color coding is based on the 3-color mPRM classification model shown in Figure 2B.
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and responders (n  19) as 10 months (95% CI  7.5, 13) and 35
months (95% CI  10, 60), respectively.
Combining the 2 mPRM indices into a 3-tier model im-
proved the potential of the mPRM to predict overall survival
(Figure 4C; P  .002). Median survivals of the 3 groups were 8.1
months (95% CI  6.1, 10) for nonresponders, 17 months (95%
CI  8.5, 26) for intermediate, and unattained for responders. A
pairwise comparison of the individual pools generated signifi-
cant results only when comparing nonresponders to either in-
termediate (P  .007) or responders (P  .005). No significant
differences were observed between intermediate and responders
(P  .2). When comparing the model to the patient clinical
metrics (Table 1), the combined mPRM model was found to
significantly vary only for patient age (P  .002), initial tumor
volume (P  .01), radiological response (P  .02), and surgical
extent (P  .04). In short, patients identified as nonresponders
were found to be older, had larger initial tumors, underwent
biopsies and, as expected, were diagnosed as having progressive
disease by radiological response.
Including the intermediate group demonstrated improved
performance in the 3-tier model for predicting overall survival
beyond what was observed in the single mPRM indices as well as
the single-parameter PRM and composite PRM models. Further
confirmation was established using a Cox regression analysis
with forward entry to assess in a multivariate statistical model
which of the single mPRM or PRM schemes provided a better fit
to the survival data than what was observed by the 3-tier mPRM
model. The Cox regression showed that no further improvement
was obtained beyond the inclusion of the 3-tier mPRM in the
statistical model (P  .003). Controlling for patient age, a known
predictor of outcome, did not alter the statistical model results.
DISCUSSION
Because of limited treatment efficacy and radiological phenom-
ena such as pseudoprogression, accurately assessing the thera-
peutic response of gliomas remains a challenge. The updated
response assessment criteria for high-grade gliomas reaffirmed
the use of anatomical MRI for assessing tumor response to
treatments (4). These recommendations suggest evaluating tu-
mor evolution over time based on structural changes observed
on both T1-weighted post-Gd and fluid attenuation inversion
recovery images 10 to 12 weeks after the start of treatment.
Recent studies have shown that morphological changes occur
after physiological modifications that may be captured by quan-
titative MRI techniques (11, 25). The goal of this study was to
evaluate a voxel-based approach that generates a response bio-
marker from 2 physiologically sensitive parameters capable of
assessing patient survival after treatment. In this study, mPRM
was demonstrated using ADC and rCBV maps and evaluated for
how well it predicted overall survival of glioma patients accrued
as part of a single-site prospective imaging trial.
Voxel-tracking techniques for assessing responses that
demonstrated the value of separating image voxels based on
changes in the voxel parametric value from pre- to midtherapy
was first introduced in 2005 (25). This approach strongly corre-
lated with a radiological response beyond what was observed
using whole-volume tumor summary statistics derived from a
histogram analysis (ie, mean change). The voxel-based tech-
nique PRM has been shown to be an independent indicator of
overall survival as early as 3 weeks after treatment is initiated
when applied to either ADC or rCBV and the composite of both
(11, 20, 31). As previously reported, PRMADC, PRMrCBV, and
the composite PRM model were also found to significantly
stratify the patient population (P  .012, .033, and .005, respec-
tively). Although mPRM is analogous to previously published
work, the strength of this methodology versus its predecessors is the
retention of spatial information that is lost in the composite of
PRMADC and PRMrCBV (31). The mPRM technique is a truly
voxel-based technique—not a pseudorepresentation of individual
PRM analyses of ADC and rCBV. Only 2 of the 9 possible metrics
Figure 4. Survival analysis of mPRM biomarkers. Kaplan–Meier survival plots for overall survival are presented for
mPRMADC/rCBV0 (A) and mPRMADC0/rCBV (B), where subjects are stratified based on cutoffs determined by ROC anal-
ysis (see Figure 2). (C) Overall survival plot for the 3-tier mPRM model. This model separates subjects into 3 groups: re-
sponders (mPRMADC/rCBV0  2.6%; mPRMADC0/rCBV  4.8%), nonresponders (mPRMADC/rCBV0  2.6%;
mPRMADC0/rCBV  4.8%), and intermediate (remaining combinations).
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derived from mPRM, mPRMADC/rCBV0, and mPRMADC0/rCBV were
found to be highly predictive of survival after chemoradiother-
apy. When combined into a 3-tier model, the potential for
predicting overall survival was found to improve over the indi-
vidual mPRM biomarkers. This highlights the importance of
utilizing methods that integrate multiple parameters into a sin-
gle response map for treatment assessment that can retain spa-
tial information.
Although DW-MRI has become a routine sequence used in
most neurological exams, precautions must be taken when ac-
quiring DSC-MRIs to reduce errors in the rCBV measurements.
This study implemented all recommendations by Paulson et al.
(35) for reducing the impact of the BBB leakage and the T1-
weighting effect on CBV measurements. In short, the following
protocols were employed: (1) a preinjection of contrast agent
before a second bolus (used for the DSC-MRI experiment) to
decrease the BBB leakage, (2) a long TR (1.5 to 2 s) to further
reduce the T1-weighting effect, and (3) the measurement and use
of the arterial input function for each DSC experiment.
The mPRM technique is an extension of the PRM method
described in previously published work and as such raises the
same issues: changes in the volume of interest size over time and
registration. As such, no significant changes of tumors sizes
were observed before or 3 weeks after the initiation of treatment
in this patient cohort. Moreover, variations observed were below
interobserver variability as previously reported for manually
tracing brain tumors (36). Problems linked to registration have
been extensively discussed in several publications (11, 37, 38).
These studies indicate that image-processing approaches can be
used effectively to coregister brain MRI data, and registration
techniques that apply deformable registration algorithms are
also widely available and provide ample flexibility for using
mPRM in a wide variety of clinical studies. Because of the
limited patient cohort used in this study, the patient character-
istics presented in Table 1 were not controlled for in the Cox
regression statistical model when evaluating the different PRM
indices. Nevertheless, the mPRM technique can potentially pro-
vide a new imaging methodology for assessing treatment re-
sponse using multiple parametric maps in brain tumor patients.
The efficacy of this technique will have to be verified in larger
prospective clinical trials, and trials that evaluate newly targeted
drugs such as antiangiogenics will be need to be conducted to
confirm these findings.
SUMMARY
In this study, we demonstrated in a single-site prospective clinical
study an early imaging biomarker to distinguish responding from
nonresponding glioma patients to standard-of-care chemoradio-
therapy. When evaluated by mPRM and rCBV, ADC metrics, indi-
vidually known to predict treatment failure, were remarkably
found to be spatially delocalized, possibly as a result of different
tumor response mechanisms, that is, cell kill as quantified by ADC
changes and hypoxia as quantified by a reduction in rCBV values.
Merging these parametric biomarkers into a single unique and
spatially resolved metric provided additional sensitivity over indi-
vidual metrics. The mPRM technique shows significant promise as
an early and robust imaging biomarker of clinical outcome in
patients diagnosed with high-grade gliomas. The application of
mPRM could be further extended to evaluate a wide variety of
tumor types and other disease processes. Moreover, mPRM could be
adapted to include a combination of alternative MRI-based metrics,
including vascular permeability, blood flow, and extravascular
leakage as well as metrics from other modalities, including, for
example, positron emission and computerized tomography. Over-
all, mPRM is a unique and generalizable imaging biomarker capa-
ble of being applied for quantifying dynamic and spatially varying
alterations in pathologically relevant disease processes and effects
of treatment over time.
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